MEDFORD, Mass., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Hepregen Corporation, leader in the development of next generation HepatoPacTM and HepatoMuneTM cell-based in vitro assay products, announced today the publication of three scientific papers that demonstrate the unique utility of the Company’s HepatoPacTM products for predicting and understanding metabolic and cell transport pathways in both humans and rats, the latter being an important animal model often used for preclinical pharmaceutical development. The papers were published independently by researchers based at Boehringer Ingelheim Pharmaceuticals U.S. research facility located in Ridgeway, Connecticut. They presented data that clearly demonstrated the high correlation of in vitro data with outcomes seen in preclinical animal studies and human clinical trials of the anti-hepatitis C virus (HCV)-directed drug, faldaprevir. These findings included determining the metabolic fate of the drug, identification of two key metabolites, their excretion pathway, and mechanisms of metabolism and transport of metabolites into the bile canaliculi.
Help employers find you! Check out all the jobs and post your resume.
